---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-074846"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:55:12.331267+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics stockholders elect two Class I directors, ratify EY as auditor

## Summary
- Paul A. Friedman, M.D. elected as Class I director with 31,165,370 votes for, 1,762,716 withheld.
- David P. Bonita, M.D. elected as Class I director with 31,007,172 votes for, 1,920,914 withheld.
- Ratification of Ernst & Young LLP as independent auditor for FY2024: 34,994,229 for, 57,512 against, 14,440 abstaining.
- Broker non-votes of 2,138,095 on director elections; none on auditor ratification.

## SEC filing metadata
- accession: 0000950170-24-074846
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017024074846/0000950170-24-074846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017024074846/prld-20240614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-074846
- JSON: https://secwatch.observer/filing/0000950170-24-074846.json
- Plain text: https://secwatch.observer/filing/0000950170-24-074846.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.